Table 3.
The multivariate Cox regression analysis of factors predicting overall survival.
| Factors | Case No. | HR | 95% CI | p-Value |
|---|---|---|---|---|
| Age (year) | ||||
| ≤55 vs. >55 | 24/64 | 0.906 | 0.453–1.811 | 0.780 |
| Gender | ||||
| male vs. female | 70/18 | 1.715 | 0.792–3.716 | 0.171 |
| Child-Pugh score | ||||
| A vs. B–C | 59/28 | 0.144 | 0.056–0.370 | <0.001 |
| BCLC stage | ||||
| B vs. C–D | 11/77 | 1.416 | 0.536–3.745 | 0.483 |
| CLIP score | ||||
| 0-1 vs. 2-5 | 35/53 | 0.786 | 0.317–1.945 | 0.602 |
| ECOG score | ||||
| 0 vs. ≥ 1 | 47/38 | 0.296 | 0.135–0.651 | 0.002 |
| ALBI grade † | ||||
| 1 vs. 2–3 | 35/48 | 0.539 | 0.198–1.466 | 0.226 |
| Distal metastasis | ||||
| positive vs. negative | 52/36 | 1.713 | 0.841–3.488 | 0.138 |
| α-Fetoprotein level (ng/mL) ‡ | ||||
| < 400 vs. ≥ 400 | 46/40 | 0.921 | 0.457–1.857 | 0.819 |
| Combination therapy as systemic line | ||||
| 1st line vs. ≥ 2nd line | 31/57 | 1.312 | 0.660–2.606 | 0.439 |
| MTKI type | ||||
| lenvatinib vs. sorafenib | 49/39 | 0.394 | 0.183–0.849 | 0.017 |
| ICI type § | ||||
| nivolumab vs. pembrolizumab | 47/38 | 1.213 | 0.576–2.557 | 0.611 |
HR, hazard ratio; CI, confidence interval; CLIP, Cancer of the Liver Italian Program Scoring System; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group performance status scale; ALBI, albumin–bilirubin; MTKIs, multitarget tyrosine kinase inhibitors; ICIs, immune checkpoint inhibitors. † Five patients had no baseline ALBI grade data. ‡ Two patients had no baseline α-Fetoprotein level. § Three patients had accepted both nivolumab and pembrolizumab during combination therapy.